Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedMay 26, 2026
DataAggregated Company Financials
Companies63
  • 7D3.1%
  • 3M-8.2%
  • 1Y8.3%
  • YTD-20.0%

In the last week, the Life Sciences industry is up 3.1%, with Danaher up 3.0%. This means that the industry has gained 8.3% over the past year. Looking forward, earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 26 May 2026US$544.2bUS$150.3bUS$14.0b33.1x38.9x3.6x
Thu, 23 Apr 2026US$593.2bUS$148.1bUS$14.2b33.8x41.9x4x
Sat, 21 Mar 2026US$543.4bUS$147.8bUS$14.0b34.6x38.7x3.7x
Mon, 16 Feb 2026US$589.2bUS$147.7bUS$13.9b35.2x42.5x4x
Wed, 14 Jan 2026US$698.6bUS$145.8bUS$12.4b37.7x56.5x4.8x
Fri, 12 Dec 2025US$665.2bUS$145.8bUS$12.5b36x53.3x4.6x
Sun, 09 Nov 2025US$636.4bUS$145.7bUS$12.2b34.1x52.3x4.4x
Tue, 07 Oct 2025US$634.7bUS$144.3bUS$14.6b32.7x43.6x4.4x
Thu, 04 Sep 2025US$578.0bUS$144.3bUS$14.6b29.1x39.7x4x
Sat, 02 Aug 2025US$557.0bUS$143.7bUS$13.5b31.8x41.2x3.9x
Mon, 30 Jun 2025US$531.7bUS$142.9bUS$9.1b35.7x58.2x3.7x
Wed, 28 May 2025US$494.4bUS$142.8bUS$9.1b32.5x54.4x3.5x
Fri, 25 Apr 2025US$520.7bUS$142.6bUS$10.0b37.4x52x3.7x
Sun, 23 Mar 2025US$596.0bUS$143.0bUS$9.9b38.7x60.2x4.2x
Tue, 18 Feb 2025US$619.7bUS$143.3bUS$10.0b34.4x62x4.3x
Thu, 16 Jan 2025US$678.1bUS$142.4bUS$10.2b43.7x66.4x4.8x
Sat, 14 Dec 2024US$668.1bUS$142.4bUS$10.2b45.5x65.4x4.7x
Mon, 11 Nov 2024US$696.6bUS$142.4bUS$10.3b44.3x67.7x4.9x
Wed, 09 Oct 2024US$728.8bUS$141.8bUS$8.5b36.9x85.8x5.1x
Fri, 06 Sep 2024US$734.8bUS$141.8bUS$8.5b37.3x86.5x5.2x
Sun, 04 Aug 2024US$742.2bUS$140.9bUS$11.3b37.3x65.9x5.3x
Tue, 02 Jul 2024US$680.5bUS$141.3bUS$12.2b38.3x55.9x4.8x
Thu, 30 May 2024US$716.0bUS$141.5bUS$12.4b37.5x57.6x5.1x
Sat, 27 Apr 2024US$709.7bUS$141.6bUS$12.7b39.2x55.8x5x
Mon, 25 Mar 2024US$749.2bUS$142.1bUS$12.8b44.7x58.4x5.3x
Wed, 21 Feb 2024US$714.0bUS$142.2bUS$12.5b42.7x56.9x5x
Fri, 19 Jan 2024US$681.8bUS$153.8bUS$14.2b35.4x48.1x4.4x
Sun, 17 Dec 2023US$684.6bUS$153.7bUS$14.2b37.1x48.1x4.5x
Tue, 14 Nov 2023US$581.9bUS$153.8bUS$14.0b31x41.7x3.8x
Thu, 12 Oct 2023US$646.8bUS$154.6bUS$11.2b33.6x57.7x4.2x
Sat, 09 Sep 2023US$705.6bUS$154.6bUS$11.2b31.6x63x4.6x
Mon, 07 Aug 2023US$725.8bUS$154.7bUS$11.3b30.2x64.5x4.7x
Wed, 05 Jul 2023US$691.6bUS$152.4bUS$12.5b29.6x55.3x4.5x
Fri, 02 Jun 2023US$675.5bUS$152.2bUS$12.5b27.2x54x4.4x
Price to Earnings Ratio

54x


Total Market Cap: US$675.5bTotal Earnings: US$12.5bTotal Revenue: US$152.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.9x which is lower than its 3-year average PE of 56.5x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.9% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.21%
Healthcare3.12%
Life Sciences3.09%
Clinical Research and Equipment3.09%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$172.003.0%
+US$3.5b		-9.1%PE33.1x
A Agilent TechnologiesUS$114.964.0%
+US$1.2b		3.3%PE25.2x
MTD Mettler-Toledo InternationalUS$1.10k5.0%
+US$1.1b		-5.1%PE25.5x
WAT WatersUS$342.372.7%
+US$894.5m		-4.5%PE74.8x
WST West Pharmaceutical ServicesUS$316.424.1%
+US$882.4m		49.9%PE41.2x

Latest News

FTRE
US$13.22
Fortrea Holdings
7D
-3.6%
1Y
218.6%
Narrative Update • May 25

FTRE: Conservative 2026 Guidance And AI Tools May Drive Re Rating

Analysts raised Fortrea Holdings’ fair value estimate to $20.00 from $16.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E that are consistent with a series of recent price target increases across the Street. Analyst Commentary Recent Street research around Fortrea has shifted toward a more constructive tone, with several bullish analysts lifting price targets and one firm moving the stock to a higher rating category.
A
US$114.96
Agilent Technologies
7D
4.0%
1Y
3.3%
ILMN
US$144.41
Illumina
7D
1.9%
1Y
75.1%
BRKR
US$45.69
Bruker
7D
7.3%
1Y
23.0%
IQV
US$167.90
IQVIA Holdings
7D
-3.0%
1Y
19.5%
WST
US$316.42
West Pharmaceutical Services
7D
4.1%
1Y
49.9%
DHR
US$172.00
Danaher
7D
3.0%
1Y
-9.1%
Narrative Update • May 19

DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple

Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.
WAT
US$342.37
Waters
7D
2.7%
1Y
-4.5%
Narrative Update • May 18

WAT: New Product Launches And Completed Buybacks Will Support Future Upside

Analysts now set a slightly higher price target for Waters at about $478, up from about $470, reflecting updated views on its fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Waters issued earnings guidance for the second quarter of 2026, with expected total revenue between US$1.616b and US$1.631b, and for full year 2026, with expected total revenue between US$6.405b and US$6.455b on a reported basis (Corporate guidance).
ALMR
US$20.06
Alamar Biosciences
7D
-2.2%
1Y
n/a
CDT
US$1.05
CDT Equity
7D
-12.5%
1Y
-99.9%
MTD
US$1,103.09
Mettler-Toledo International
7D
5.0%
1Y
-5.1%
Narrative Update • May 15

MTD: 2026 Local Currency Sales Outlook Will Drive Future Upside

Analysts have trimmed their price target for Mettler-Toledo International from about $1,488 to roughly $1,345, citing updated assumptions that include slightly different revenue growth, profit margin, discount rate, and future P/E expectations. What's in the News Mettler-Toledo International issued new earnings guidance for the second quarter of 2026, indicating an anticipated local currency sales increase of approximately 3% (company guidance).
TECH
US$48.21
Bio-Techne
7D
6.0%
1Y
-1.0%
Narrative Update • May 12

TECH: Portfolio Rebrand And Diagnostics Expansion Will Support Stronger Future Upside

Analysts have adjusted their price target on Bio-Techne to $76.00 from $75.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Bio-Techne introduced a streamlined brand architecture that groups its offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, to align products with stages of scientific research from discovery through clinical diagnostics (Key Developments).
BNBX
US$0.38
BNB Plus
7D
-7.4%
1Y
-95.2%